Oral Lichen Planus Clinical Trial
Official title:
Nonaromatic Naphthalan - Composition Study and Biological Effects on Epithelial Tissues
This study evaluates the effectiveness of topical NAVS naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Half of participants with OLP and RAS will receive topical NAVS naphthalan in adhesive paste, while the other half will receive 0.05%-betamethasone dipropionate in adhesive paste. Our hypothesis is that NAVS could be efficient in the treatment of OLP and RAS, with effects comparable to that of topical steroids.
Non-Aromatic-Very rich in Steranes (NAVS) naphthalan is a transparent, earth mineral oil
prepared by a complex set of procedures of separations and refining, starting with a special
oil that is used as the raw material for brown naphthalane, which has been successfully used
in the treatment of psoriasis. In order to remove potentially mutagenic polycyclic aromatic
hydrocarbons (PAHs), liquid chromatography was used. UV / VIS (ultra violet / visible light)
spectrophotometry confirmed that PAHs were bellow detection threshold. Additionally, the
precise distillation process has concentrated steranes, which are important bioactive
constituents. Since steranes contain similar chemical structure as well-known bioactive
substances, such as vitamin D3 and steroid hormones, the assumption is that NAVS is
effective in the treatment of oral diseases which have immune genesis such as OLP and RAS.
Today, topical steroid preparations are considered as first-line therapy for many chronic
immune-mediated inflammatory diseases of the oral mucosa. Risks of short-term use of topical
corticosteroids are clinically insignificant, while their long-term use is not recommended
because of potential side effects, such as mucosal atrophy, secondary infection with Candida
albicans, possible systemic absorption and suppression of the adrenal gland.
Study participants are adult patients of the Department of Oral Medicine, School of Dental
Medicine in Zagreb, with a clinically and histologically proven OLP or RAS in the acute
stage of the disease.The treatment outcome of the OLP patients will be measured by clinical
improvement and subjective symptomatic relief. The outcome of RAS patients treated by NAVS
naphthalan or by betamethasone will be measured clinically by the decrease in number and
size of lesions as well as by subjective symptomatic relief over treatment period. One
member of the team, who will not evaluate the therapeutic effect, will took care of the
allocation of test and control preparations. At the end of the study, a randomization code
will be opened and statistically analysed. In both clinical and subjective domains, of both
clinical conditions, the improvement rate will be measured by comparing these readings, as
the percentual reduction of clinical scores and symptoms. Since the data will not be
normally distributed, methods of nonparametric statistics will be used: Wilcoxon test for
dependent and Mann-Withney test for independent samples. Baseline intergroup differences
will be assessed by Mann-Withney test. For the interpretation of the average values, medians
and interquartile ranges (IQR) will be used. Fisher exact test will be used to compare
gender representation among the groups. Statistical analysis will be performed using MedCalc
Software 13.0.0.0 (Acacialaan 22, 8400 Ostend, Belgium). P value lower then 0.05 (p< 0.05)
will be considered statistically significant.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05997173 -
The Regulatory Role of Immune Response in Oral Lichen Planus
|
||
Completed |
NCT02443311 -
Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus
|
Phase 4 | |
Completed |
NCT00484250 -
Study of Metronidazole and Doxycycline to Treat Oral Lichen Planus and to Compare Their Efficacy With Each Other
|
Phase 2 | |
Completed |
NCT03682562 -
Diagnostic Accuracy of Salivary DNA Integrity Index in Oral Malignant and Premalignant Lesions
|
||
Not yet recruiting |
NCT06428630 -
Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus
|
Early Phase 1 | |
Completed |
NCT04193748 -
Evaluation of Topical Pomegranate Extracts in Management of Oral Lichen Planus (A Randomized Clinical Trial)
|
Phase 4 | |
Completed |
NCT04153266 -
Oral Epithelial Dysplasia Informational Needs Questionnaire
|
||
Recruiting |
NCT06135805 -
Impact of Fluocinonide 0,05% in Oral Lichen Planus
|
N/A | |
Completed |
NCT04289233 -
Molecular & Cellular Characterisation of Oral Lichen Planus
|
||
Completed |
NCT04293718 -
Acquired Chronic Erosive Gingivitis: Clinical Relevance of Papillary Gingival Biopsy
|
||
Completed |
NCT00525421 -
A Clinical Study of Curcuminoids in the Treatment of Oral Lichen Planus
|
Phase 2 | |
Not yet recruiting |
NCT04091698 -
Clinical and Biochemical Assessment of the Effect of Topical Use of Coenzyme Q10 Versus Topical Corticosteroid in Management of Symptomatic Oral Lichen Planus: Randomized Controlled Clinical Trial
|
Phase 1 | |
Completed |
NCT03386643 -
Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus
|
Phase 2 | |
Withdrawn |
NCT03836885 -
Apremilast - Oral Lichen Planus Trial
|
Phase 2 | |
Completed |
NCT05730855 -
Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions
|
||
Completed |
NCT03257228 -
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)
|
N/A | |
Recruiting |
NCT03026478 -
Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus
|
Phase 2 | |
Completed |
NCT02858297 -
Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus
|
Phase 4 | |
Completed |
NCT02834520 -
Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus
|
N/A | |
Completed |
NCT02106468 -
The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus
|
Phase 2 |